Mutant p53 has been considered as an appealing tumour-specific antigen target for immunotherapy, but limited success has been achieved in this field due to the inefficient presentation of mutant p53 antigen on cells for recognition [225,226,227,228]. Here, TP53 is linked to neoplasm.